Preventive therapy for steroid-induced osteoporosis in interstitial lung disease
Abstract
We do not have to accept bone loss and high fracture rates as inevitable consequences of high-dose glucocorticoid therapy. The assessment of the risk of osteoporosis should be an integral part of the decision to commence glucocorticoid therapy. The decision to initiate a preventive strategy should be taken on the basis of the expected risk of developing osteoporosis. This risk should be evaluated on the basis of the expected duration of corticosteroid therapy, the needed dose, the drug given, and the presence of risk factors. Pro and cons of calcium, vitamin D, inhibitors of bone resorption, stimulators of bone formation, and thiazide diuretics are described in the light of the presence of an interstitial lung disease.
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.